Preparation and characterisation of silica-based nanoparticles for cisplatin release on cancer brain cells

IET Nanobiotechnol. 2020 May;14(3):191-197. doi: 10.1049/iet-nbt.2019.0239.

Abstract

In the present work, the preparation, characterisation, and efficiency of two different silica nanostructures as release vehicles of Cisplatin are reported. The 1-hexadeciltrimethyl-ammonium bromide templating agent was used to obtain mesoporous silica nanoparticles which were later loaded with Cisplatin. While sol-gel silica was very fast prepared using an excess of acetic acid during the hydrolysis-condensation reactions of tetraethylorthosilicate and at the same time the Cisplatin was added. Several physicochemical techniques including spectroscopies, electronic microscopy, X-ray diffraction, N2 adsorption-desorption were used to characterise the silica nanostructures. An in vitro Cisplatin release test was carried out using artificial cerebrospinal fluid. Finally, the toxicity of all silica nanostructures was tested using the C6 cancer cell line. The spectroscopic results showed the suitable stabilisation of Cisplatin into the two different silica nanostructures. A large surface area was obtained for the mesoporous silica nanoparticles, while low areas were obtained in the silica nanoparticles. Cisplatin was released faster from mesoporous silica channels than from inside of aggregates nanoparticles silica. Cisplatin alone, as well as, cisplatin released from both silica nanostructures exerted a toxic effect on cancer cells. In contrast, both silica structures without the drug did not exert any toxic effect.

MeSH terms

  • Animals
  • Brain Neoplasms / metabolism*
  • Cell Line, Tumor
  • Cisplatin* / chemistry
  • Cisplatin* / pharmacokinetics
  • Drug Carriers* / chemistry
  • Drug Carriers* / pharmacokinetics
  • Nanoparticles / chemistry*
  • Rats
  • Silicon Dioxide / chemistry*

Substances

  • Drug Carriers
  • Silicon Dioxide
  • Cisplatin